Rat studies comparing 11C-FMAU, 18F-FLT, and 76Br-BFU as proliferation markers.

UNLABELLED We analyzed and compared 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-[methyl-(11)C]thymine ((11)C-FMAU), 3'-deoxy-3'-[(18)F]fluorothymidine ((18)F-FLT) and 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-[(76)Br]bromouracil ((76)Br-BFU) with respect to tissue uptake, DNA incorporation, and excretion modulation in rats. The goal of the investigation was to evaluate the efficiency of the 3 nucleoside tracers as potential tracers for measuring proliferation. METHODS Sprague-Dawley rats were divided into 3 groups and administered 5 MBq (11)C-FMAU, 1 MBq (18)F-FLT, or 2 MBq (76)Br-BFU. For each tracer, a subgroup was also administered 6 mg/kg cimetidine. The rats in the (11)C-FMAU group were killed at 5, 20, 40, 60, and 80 min after injection; the rats in the (18)F-FLT group were killed at 80 min and 2 and 4 h; and the rats in the (76)Br-BFU group were killed at 5, 20, 40, and 80 min and 2, 4, 6, and 24 h. Samples of blood, liver, kidney, spleen, and intestine were taken, and the radioactivity was measured. DNA separation was made in the samples of spleen, and the radioactivity in the DNA fraction was measured. RESULTS Maximal uptake of radioactivity was seen in the spleen and intestine, organs with active DNA synthesis. The highest relative radioactivity uptake was at 60 min in the (11)C-FMAU groups and at 4 h in the (18)F-FLT group. In the (76)Br-BFU group, the uptake increased gradually during the observation period, and uptake of radioactivity increased markedly in rats receiving cimetidine. Cimetidine did not affect radioactivity uptake in the (11)C-FMAU or (18)F-FLT groups. The fraction of radioactivity in DNA was 78% in spleen at 60 min in the (11)C-FMAU group, 80% at 60 min and 97% at 4 h in the (76)Br-BFU group. The DNA-incorporation was only 2% in the (18)F-FLT group. CONCLUSION (76)Br-BFU predominantly incorporates into DNA and has great potential as a PET tracer for the assessment of proliferation in vivo. (11)C-FMAU also may have potential as a proliferation marker, but the observation time is limited. (18)F-FLT does not incorporate into DNA and is therefore not a direct marker of proliferation.

[1]  S. Adelstein,et al.  Tumor Targeting Potential and Metabolism of 5‐[125I]Iodo‐2′‐Deoxyuridine Injected Intratumorally in Patients with Breast Cancer a , 1993, Annals of the New York Academy of Sciences.

[2]  E. De Clercq,et al.  Synthesis and antiviral activity of 5-thien-2-yl-2'-deoxyuridine analogues. , 1993, Journal of medicinal chemistry.

[3]  T. Koizumi,et al.  Effects of probenecid and cimetidine on the renal excretion of 3'-azido-3'-deoxythymidine in rats. , 1995, The Journal of pharmacology and experimental therapeutics.

[4]  G. Antoni,et al.  Synthesis of L- and D-[methyl-11C]methionine. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[5]  M. Bergström,et al.  Elimination of nonspecific radioactivity from [76Br]bromide in PET study with [76Br]bromodeoxyuridine. , 1999, Nuclear Medicine and Biology.

[6]  M. Bergström,et al.  In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  J. Ryser,et al.  [76Br]Bromodeoxyuridine, a potential tracer for the measurement of cell proliferation by positron emission tomography, in vitro and in vivo studies in mice. , 1999, Nuclear medicine and biology.

[8]  J Grierson,et al.  Utilization of labeled thymidine in DNA synthesis: studies for PET. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[9]  H. Lundqvist,et al.  PRODUCTION OF 76BR BY A LOW-ENERGY CYCLOTRON , 1998 .

[10]  K. Ishiwata,et al.  Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  T. Borght,et al.  Brain tumor imaging with PET and 2-[carbon-11]thymidine. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  T Ido,et al.  Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  A. Harris,et al.  The influence of high dose hydroxyurea on the incorporation of 5-iodo-2-deoxyuridine (IUdR) by human bone marrow and tumour cells in vivo. , 1993, British Journal of Cancer.

[14]  A. Shields,et al.  Radiosynthesis of 3'-deoxy-3'-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. , 2000, Nuclear medicine and biology.

[15]  P. Martiat,et al.  In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  J. Bading,et al.  Pharmacokinetics of the thymidine analog 2'-fluoro-5-[(14)C]-methyl-1-beta-D-arabinofuranosyluracil ([(14)C]FMAU) in rat prostate tumor cells. , 2000, Nuclear medicine and biology.

[17]  N. Kajimura,et al.  A rapid anticancer drug screening assay by [14C] thymidine uptake in cultured human cancer cells. , 1992, European Journal of Cancer.

[18]  PETER ALEXANDER,et al.  Cancer Chemotherapy , 1968, Nature.

[19]  B. Långström,et al.  Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  D. Mankoff,et al.  Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  D. Mankoff,et al.  Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[22]  B. Långström,et al.  Simple production of 77Br− and 123I− and their use in the labelling of [77Br]BrUdR and [123I]IUdR , 1979 .

[23]  A. Shields,et al.  Development of labeled thymidine analogs for imaging tumor proliferation. , 1996, Nuclear medicine and biology.

[24]  P. Lindholm,et al.  Carbon-11-methionine uptake in squamous cell head and neck cancer. , 1998, Journal of Nuclear Medicine.

[25]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[26]  M. Bergström,et al.  Analysis of 76Br-BrdU in DNA of brain tumors after a PET study does not support its use as a proliferation marker. , 2001, Nuclear medicine and biology.

[27]  D. A. Rey,et al.  Effects of cytosine arabinoside and hydroxyurea on the synthesis of deoxyribonucleotides and DNA replication in L1210 cells. , 1990, Advances in enzyme regulation.

[28]  R P Williams,et al.  Noninvasive grading of musculoskeletal tumors using PET. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  M. Bergström,et al.  Synthesis of [76Br]bromofluorodeoxyuridine and its validation with regard to uptake, DNA incorporation, and excretion modulation in rats. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[30]  J. Baranowska-Kortylewicz,et al.  Radiolabeling kit/generator for 5‐radiohalogenated uridines , 1994 .

[31]  F. Roch-Ramel,et al.  Renal secretion of 3'-azido-3'-deoxythymidine by the rat. , 1990, The Journal of pharmacology and experimental therapeutics.

[32]  P. Carnochan,et al.  Radiolabelled 5'-iodo-2'-deoxyuridine: a promising alternative to [18F]-2-fluoro-2-deoxy-D-glucose for PET studies of early response to anticancer treatment. , 1999, Nuclear medicine and biology.

[33]  P. Conti,et al.  Synthesis of 2'-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET. , 1995, Nuclear medicine and biology.

[34]  K. Leenders,et al.  [76Br]Bromodeoxyuridine PET in tumor-bearing animals. , 2001, Nuclear medicine and biology.

[35]  K. Någren,et al.  Carbon-11-methionine and PET in evaluation of treatment response of breast cancer. , 1993, British Journal of Cancer.